Researchers reviewed published clinical trials in order to summarize the results of immunotherapy and endothelin receptor antagonists for the treatment of castration-resistant prostate cancer (CRPC). They found that both types of treatment improve overall survival, but do not significantly improve progression-free survival or time to disease progression. The researchers feel that further studies are warranted.
Significant progress has been made in the understanding of AR-dependent and AR-independent mechanisms involved in the development of CRPC. This may lead to identification of new therapeutic targets and improved therapy.
The FDA recently approved a combination of two drugs—abiraterone and the steroid prednisone—for the treatment of castration-resistant prostate cancer (CRPC) in patients who have previously been treated with chemotherapy. Scientists are now testing whether the combination treatment is beneficial for patients who have not been treated with chemotherapy. Interim results indicate that the treatment doubles progression-free survival and increases overall survival from 30.1 months to 35.3 months.
Advanced prostate cancer patients used to be treated with palliative chemotherapy that did not improve survival. But in the past decade, researchers have introduced several new therapies for castration-resistant prostate cancer (CRPC) and related complications. These drugs include cabazitaxel (Jevtana), abiraterone acetate (Zytiga), enzalutamide (Xtandi), sipuleucel-T (Provenge), radium-223, and denosumab (Xgeva or Prolia). Two researchers recently performed a cost-benefit analysis on these new therapies. They say that costs will come down as treatment strategies—including precisely timed combinations of drugs—are refined to minimize progression and side effects.
Radium Ra 223 Dichloride will be considered as a treatment for patients who have castration-resistant prostate cancer with bone metastases under the FDA’s priority review program. The filing is based on the 922 patient phase III ALSYMPCA trial, of radium-223 plus current standard of care, or placebo plus current standard of care.